The Pharmacy team of the Ministry of Health of Patricia Lacruz placeholder image has many projects on the table. And now he has to step on the accelerator to start up again those that the Covid-19 have left in stand-by.
This was confirmed this Tuesday during the ‘II Health Observatory Symposium: The Lessons of Covid-19’, organized by EL ESPAÑOL and Invertia, the general director of Pharmacy, Patricia Lacruz.
On the second day of this appointment with the health sector, the general director of Pharmacy of the Carolina Darias ministry It has undertaken to study a possible change in the payment model towards charging for services. A model highly demanded by pharmacy offices and that opens the door to a new remuneration formula.
In addition, as Lacruz herself has advanced, this possible modification will be framed in the new Drug Law although, at the moment, it is not possible to advance much. “If the sector considers that it is a question to raise, there will be an active listening and an analysis on our part,” he added.
In the same way, Lacruz has advanced that his department is working on a modification of the Pharmaceutical copayment. Something that was foreseen in the pact of the Coalition Government, but that had not come to fruition.
On how these changes will be, Lacruz has put on the armor and has preferred not to say much. What it has done has been to open up the possibility that they are “studying” to expand the current three contribution tranches based on the income of the general population.
If the Cid Campeador is the Castilian pride par excellence, the coronavirus vaccines they are the pride of science. Evidence of this has been left by most of the speakers who have participated this Tuesday in the second day. Quote of which the representatives of the national and international ‘Farmas’ that lead the search for new treatments against Covid-19 have taken part.
An industry that has asked for its chair in the process of Spanish redindustrialization and that requires better investments, as Fernández Alcade, CEO of Merck in Spain. “If we want to be Germany or Sweden we have to invest 7% of the country’s GDP in healthcare.”
And, the pharmaceutical industry has everything to be the Tizona of a Cid Campeador (which is Spain) capable of leading the economic recovery in Europe. An international benchmark in clinical trials, representatives of large pharmaceutical companies in Spain have asked the authorities for more investment in R&D to be an “investment pole” on which the economic recovery of the country is based.
Recovery that, according to the political opposition, involves investing and “knowing how to count.” At least that’s what he has claimed Ana Pastor, deputy of the Popular Party and former Minister of Health, who has proposed the creation of a juglar pandemics (continuing with similes). Although she has not used the Castilian epic but a specific training: the creation of a specialty of risk communication.
In his opinion, this figure should be linked to the Spanish Public Health Agency and be the transmitter of the progress of the pandemic through a “transparent” perspective. In addition, Pastor has served as a scourge of the Government, as a member of the opposition, to recriminate the implementation of evaluations of health professionals “when what they need is support and resources.”
That vaccines have been a success against Covid-19 it is not going to stay only in the Wuhan virus. The heads of institutional relations of several pharmaceutical companies have assured during the Observatory that the times in which a drug took 15 years from being successful in mice until it was passed to humans “have ended.”
They assure that, thanks to the Covid-19, the relationship between pharmaceutical companies and administrations has been optimized for the benefit of “patients”. “A robust and digitized healthcare system that allows biomarkers to be measured will help develop personalized medicine,” they argued.
Your opinion agrees with that of President of Farmaindustria and CEO of Rovi, Juan López-Belmonte. “We need to be competitive and send the message that Spain believes and is committed to innovation. And the best way is for us to have the same approval times for medicines and prices as European countries,” he assured.
The CSIC vaccine
But, as not all battles can be won (even El Cid lost his son in Consuegra’s), there is always a stone in the way of science. In the Spanish case, the ‘defeat’ is the total stoppage of the CSIC coronavirus vaccine led by Mariano Esteban.
The suspension sine die of the trial in patients was due, as explained María Jesús Lamas, director of the AEMPS, at an “uncertain risk” but “serious enough” to suspend the human trial.
And, although vaccines are taking over today, we must not forget the development of drugs against Covid-19. In it are companies like Lilly, Rooms and PharmaMar. José Antonio Sacristán, medical director of Lilly Spain, and Pablo de Mora, general director for Spain and Portugal of Sobi, have demanded that the Administrations “prioritize” drugs against the coronavirus, given the health emergency.
For its part, the Spanish company faces the last phase of the clinical trial of its drug, Aplidin, which has also shown positive results in persistent Covid, as confirmed by its president, José María Fernández Sousa-Faro, during the second day of the Health Observatory.
Precisely about clinical trials they have spoken Javier Lightweight, Director of GDD and Head of Clinical Trials at Novartis and Teresa Millán Rusillo, Director of Corporate Affairs at Lilly, who have claimed to eliminate bureaucratic obstacles to speed up the launch of investigations.
Looking to the future, healthcare cannot only be the lever for economic change. Also social. At least he thinks so Alberto de Rosa, European CEO of Centene Corporation, who sees Spain as a place to live. No thanks to the sun or the classic heroes: for their healthcare system.
During his conversation with the deputy director of Invertia, Arturo Criado, the expert recalled that Spain has a health sector that can be “focus of attraction” so that “people from other countries come to reside here.” “We have to see it as an opportunity and prepare for it.”